Melanoma bulk-tumor transcriptomic and single-cell (sc)RNAseq data have identified other potential biomarkers of response and survival in patients treated with sequential ICB therapy (anti-CTLA-4 then anti-PD-1). Here, CTLA4 is linked to neoplasm.